Effect of orbofiban on the relative risk (95% confidence interval) for the primary end point, myocardial infarction, and bleeding
| Event . | PlA2noncarrier . | PlA2 carrier . | P value for treatment interaction3-150 . |
|---|---|---|---|
| Primary endpoint3-151 | |||
| Orbofiban | 0.73 (0.51, 1.06) | 1.37 (0.75, 2.51) | .10 |
| 50/30 mg | 0.74 (0.48, 1.14) | 1.61 (0.84, 3.08) | |
| 50/50 mg | 0.73 (0.46, 1.14) | 1.04 (0.47, 2.26) | |
| Myocardial infarction3-151 | |||
| Orbofiban | 0.59 (0.23, 1.53) | 2.46 (0.70, 8.67) | .08 |
| 50/30 mg | 0.50 (0.15, 1.65) | 3.24 (0.89, 11.82) | |
| 50/50 mg | 0.70 (0.23, 2.14) | 1.37 (0.28, 6.80) | |
| Bleeding3-152 | |||
| Orbofiban | 1.873-153 (1.29, 2.71) | 0.87 (0.46, 1.64) | .05 |
| 50/30 mg | 1.55 (1.02, 2.36) | 0.82 (0.39, 1.69) | |
| 50/50 mg | 2.233-153 (1.49, 3.34) | 0.94 (0.44, 2.03) |
| Event . | PlA2noncarrier . | PlA2 carrier . | P value for treatment interaction3-150 . |
|---|---|---|---|
| Primary endpoint3-151 | |||
| Orbofiban | 0.73 (0.51, 1.06) | 1.37 (0.75, 2.51) | .10 |
| 50/30 mg | 0.74 (0.48, 1.14) | 1.61 (0.84, 3.08) | |
| 50/50 mg | 0.73 (0.46, 1.14) | 1.04 (0.47, 2.26) | |
| Myocardial infarction3-151 | |||
| Orbofiban | 0.59 (0.23, 1.53) | 2.46 (0.70, 8.67) | .08 |
| 50/30 mg | 0.50 (0.15, 1.65) | 3.24 (0.89, 11.82) | |
| 50/50 mg | 0.70 (0.23, 2.14) | 1.37 (0.28, 6.80) | |
| Bleeding3-152 | |||
| Orbofiban | 1.873-153 (1.29, 2.71) | 0.87 (0.46, 1.64) | .05 |
| 50/30 mg | 1.55 (1.02, 2.36) | 0.82 (0.39, 1.69) | |
| 50/50 mg | 2.233-153 (1.49, 3.34) | 0.94 (0.44, 2.03) |
Dose effects shown in bold. Risks are relative to the placebo group.
Analysis of the interaction between orbofiban and placebo, and the PlA2 genotype.
Results of a proportional hazards analysis adjusted for age and sex.
Results of a proportional hazards analysis adjusted for age, sex, and country.
P < .001 relative to placebo.